



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/195, 31/20, 31/23, A23K 1/18		A1	(11) International Publication Number: WO 00/00189
			(43) International Publication Date: 6 January 2000 (06.01.00)
(21) International Application Number: PCT/US99/14344		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 June 1999 (24.06.99)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 09/106,295 29 June 1998 (29.06.98) US			
(71) Applicants: COLGATE-PALMOLIVE COMPANY (US/US); 300 Park Avenue, New York, NY 10022 (US). COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US/US); 601 South Howes, Fort Collins, CO 80521 (US).			
(72) Inventors: DAVENPORT, Deborah, J.; 1633 E. 318 Road, Lecompton, KS 66050 (US). GROSS, Kathy, L.; 3627 N.W. 94th, Topeka, KS 66618 (US). OGILVIE, Gregory, K.; 2000 Brickwood Drive, Fort Collins, CO 80525 (US). HAND, Michael, S.; Route 1, Box 430, Maple Hill, KS 66507 (US).			
(74) Agent: BARANCIK, Martin, B.; Colgate-Palmolive Company, 909 River Road, P.O. Box 1343, Piscataway, NJ 08855-1343 (US).			
(54) Title: METHOD FOR REDUCING THE DAMAGING EFFECTS OF RADIATION THERAPY ON ANIMAL SKIN AND MUCOSA			
(57) Abstract			
<p>The severity of damage caused to the skin and mucosa of animals with cancer undergoing radiation therapy is mitigated by feeding the animal a nutritionally balanced food composition containing omega-6 polyunsaturated fatty acids which are supplemented with a mixture of an omega-3 polyunsaturated fatty acids and arginine.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Trinidad and Tobago	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

**METHOD FOR REDUCING THE DAMAGING EFFECTS OF
RADIATION THERAPY ON ANIMAL SKIN AND MUCOSA**

BACKGROUND OF THE INVENTION

5

10 **Field of the Invention**

The present invention relates to a method of reducing damage to skin and mucosa in pet animals such as dogs and cats wherein the pet is afflicted with cancer and is subjected to radiation therapy, the method including a food composition to be used for this purpose.

15 **The Prior Art**

Clinical radiation therapy in animals with cancer is known to induce biochemical changes in normal animal tissues and cells resulting in damage thereto. A need clearly exists for means to ameliorate the damage to a patient's normal tissues during radiation therapy. Previous methods of affording such amelioration include the administration to the patient of chemical agents which often have undesirable side effects on the patient.

SUMMARY OF THE INVENTION

25 The present invention is premised on the discovery that radiation damage to normal cells of animals with cancer undergoing radiation therapy can be reduced by fortifying the animal with a diet supplemented with a mixture of polyunsaturated omega-3 fatty acids and arginine.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

30 The method of reducing the damaging effects of radiation therapy in animals with cancer, and particularly pet animals, pursuant to the present invention, is provided by feeding the animal undergoing such therapy with a food composition which contains omega-6 fatty acids as a nutrient and in which the nutrient content of the food is supplemented to contain on a dry matter basis

about 2.5 to about 7.5% omega-3 fatty acids, and about 2.0 to about 3.5% arginine, the weight ratio of omega-3 to omega-6 fatty acid in the food being in the range of about 0.3:1 to 3.5:1.

It is particularly advantageous in the practice of the present invention that the nutrient 5 content of the food composition used in the method contain about 27 to about 35% on a dry matter basis of fat and about 15 to about 27% on a dry matter of carbohydrate, the term "dry matter basis" when used herein meaning the nutrient content of the food product after moisture is removed. A food composition of this type is disclosed in co-pending patent application USSN 08/544,421, which composition is effective in mitigating the severity of metabolic disturbances in animals with 10 cancer. The art however has provided no link between feeding this food composition to animals with cancer to reduce metabolic disturbance and the reduction in damage to normal skin and mucosa cells when such animals, having been fed such food, are exposed to radiation therapy.

The present invention is generally intended to apply to all forms of pet food including dry, 15 canned or intermediate moisture pet food products, as these terms are recognized by those skilled in the art of pet food formulation and manufacturing, which foods conventionally contain omega-6 fatty acids as essential nutritional ingredients.

The pet food composition of the present invention is not intended to be restricted by any 20 specific listing of proteinaceous, fat or carbohydrate ingredients or product form, since these will be entirely dependent upon the nutritional balance of the ration desired as well as their availability to the pet food manufacturer. Generally, aside from nutritionally balancing ingredients such as vitamins, minerals and the like, the food compositions of the present invention have a moisture content of about 10 to about 90% by weight and preferably about 65 to about 75% by weight and 25 are formulated having a nutrient content listed in Table I below.

TABLE I

Nutrient	Nutrient Content % (Dry Matter Basis)
Carbohydrate	about 15 to about 27
Protein	about 35 to about 48
Fat	about 27 to about 35
Omega-6 Fatty Acids	about 2.0 to about 6.0
Omega-3 Fatty Acids	about 2.5 to about 7.5
Arginine	about 2.0 to about 3.5
Nutritional balancing agents such as vitamins (A, B1, B2, B6, E) and minerals (Ca, P, Na, K, Mg, Fe, Cl)	about 0.4 to about 1.0

The critical factor insofar as the present invention is applicable to the amelioration of radiation therapy cell damage is the presence of a mixture of omega-3 polyunsaturated fatty acids 5 and arginine in the proportions specified in Table I above, in a nutritionally balanced pet food composition which includes omega-6 polyunsaturated fatty acids as nutrients.

The fat and carbohydrate nutrients used to prepare the pet food compositions of the present invention may be supplied by ingredients such as meat, meat by-products, other animal protein 10 sources and grains as the food source. By meat is meant the flesh of cattle, swine, sheep, goat, horses, and other mammals as well as poultry and fish. Meat by-products include, but are not limited to lungs, kidneys, brain, livers, and stomachs and intestines freed of their contents. Additionally, meat, meat by-products, and other animal protein source mixtures are suitable for use 15 in the pet food of this invention. The nutrient ingredients may also include amounts of cereal grains such as wheat, corn, barley and rice and fibrous bulking materials such as cellulose, beet pulp, peanut hulls or soy fiber.

A typical canned dog food product useful in the practice of the method of the present invention is prepared from a mixture of the following ingredients:

TABLE II

Ingredient	% By Weight
Water	25 - 30
Lungs, Beef Lobs	40 - 45
Liver	6-10
Chicken	5-8
Rice	4-8
Fish Oil (omega-3 and omega-6 fatty acid source)	5-8
Cellulose	0.5-2
Beef Pulp	0.5-2
Inorganic Salts (calcium carbonate, iron oxide, potassium citrate)	0.5-2
Arginine	0.2-0.6
Vitamins	0.01-0.2
Taurine	0.02-0.2
Minerals	0.01-0.2

In preparing a pet food product useful in the practice of the present invention, the nutrient composition is adjusted so that the concentration of omega-3 polyunsaturated fatty acids is present

5 in the animal food product of the present invention at a concentration of about 2.5 to about 7.5% on a dry matter basis and preferably about 7.0 to about 7.5% on a dry matter basis, when the omega-6 polyunsaturated fatty acids are present in the pet food product at a concentration of about 2.0 to about 6.0% on a dry matter basis.

10 The omega-3 and omega-6 polyunsaturated fatty acids are most conveniently provided by fish oils such as menhaden, mackerel, herring, anchovy and salmon which all have significant levels of omega-3 and omega-6 polyunsaturated fatty acids. Omega-3 polyunsaturated fatty acids C20:5 eicosapentaenoic acid and C22:6 docosahexaenoic acid are typical of fish oil and together comprise about 25-38% by weight of the fish oil. Omega-6 polyunsaturated fatty acids include

15 linoleic acid and arachidonic acid and are present in the fish oils at lesser concentrations generally less than about 10% by weight.

The pet food product of the present invention is supplemented with arginine to contain about 2.0 to about 3.5% on a dry matter basis and preferably about 3.0 to about 3.5% on a dry matter basis. The arginine and fish oil components of the pet food product of the present invention are incorporated in the food product during the processing of the formulation, as for example,

5 during and after mixing of the ingredients of the pet food. Distribution of these components can be accomplished by conventional means.

Other additives may be included in this pet food as needed. These other additives include flavoring, vitamins, minerals, coloring and mixtures thereof. These additives are added for

10 nutritional purposes and palatability. Suitable amounts are easily determined by a person having ordinary skill in the art. However, up to about 5% of these ingredients are customarily used. Ingredients in this category are exemplified by iron oxide, sodium chloride, potassium citrate, potassium chloride, and other edible salts, flavoring, vitamins, minerals and coloring.

15 The pet food products prepared in accordance with the practice of the present invention are prepared by mixing ground animal and poultry proteinaceous tissues with the remaining ingredients which include fish oils, arginine, cereal grains and other nutritionally balancing ingredients and special purpose additives such as vitamin and mineral mixtures, inorganic salts, cellulose and beet pulp bulking agents and the like. Water sufficient for processing is also added.

20 A vessel suitable for heating while blending the components is used.

Heating of the ingredient mix may be effected in any suitable manner as, for example, by direct steam injection or by using a vessel fitted with a heat exchanger. Following the addition of the last ingredient, the mixture is heated to a temperature ranging from approximately 70°F to

25 about 140°F. Temperatures outside of this range are acceptable but may not be commercially practical without the use of other processing aids. When heated to the appropriate temperature, the material is in the form of a thick liquid. The thick liquid product is then filled into cans. A lid is applied and the container is hermetically sealed. Next, the sealed can is placed into conventional equipment designed to sterilize the contents. This is usually accomplished by heating to

30 temperatures above 230°F for an appropriate time which is dependent on the exact temperature and formula.

For the purposes of a complete understanding of the present invention it should be recognized that the term pet food composition is generally intended to apply to commercially sold and nutritionally balanced pet food which provides the sole food intake for the pet animal.

5 The following Example is intended to describe specific but non-limiting embodiments of the present invention.

EXAMPLE

Preparation of Pet Food Product

10

A pet food product useful in the practice of the present invention was prepared by blending a mixture of the ingredients listed in Table III below and heating the mixture to 135°F for 15 minutes followed by filling cans at 110°F to form a thick liquid which was canned and sterilized at 250°F for 83 minutes.

TABLE III
INGREDIENT COMPOSITION OF PET FOOD PRODUCT

Ingredient	pounds/100 pounds
Lungs, Beef	44.00
Water	26.12
Liver, Pork	8.00
Rice, Parboiled	6.00
Menhaden Fish Oil (l)	5.75
Chicken, Mechanically Deboned	5.50
Natural Flavor *	1.50
Cellulose	1.00
Beef Pulp	1.00
Potassium Citrate	0.50
L-Arginine	0.30
Calcium Carbonate	0.10
Vitamin mix**	0.08
Mineral Mix***	0.05
Taurine	0.05
Red Iron Oxide	0.03
Choline Chloride	0.02
TOTAL	100.00

* Available from Applied Food Biotechnologies

** Available from Roche Animal Health and Nutrition

*** Available from J.M. Huber Corporation

(I) Fatty Acid Composition of Menhaden Oil ** Wt.% of Fatty Acid**

Palmitic (16:0)	16.2
Palmitoleic (16:1)	11.6
Stearic (18:0)	2.9
Oleic (18:1)	10.9
Linoleic (18:2)	1.2
Linolenic (18:3)	1.6
Octadecatetraenoic (18:4)	3.2
Eicosapentaenoic (20:5)	14.1
Docosahexaenoic (22:6)	11.9
Eicosanoic (20:1)	1.3
Arachidonic (20:4)	1.7
Docosapentaenoic (22:5)	2.4

**** Commercially available from Zapata Protein, Inc. Fatty acid concentrations <1% are not included

Analysis of the retorted pet food product prepared from the ingredients of Table III indicated, as recorded in Table IV indicated the presence of the following constituents:

TABLE IV
NUTRIENT COMPOSITION OF PET FOOD PRODUCT

Nutrient	% by Weight	% Dry Matter
Moisture	71.6	N/A
Protein	10.7	37.8
Fat	9.3	32.6
Carbohydrate	6.1	21.4
Fiber, crude	1.0	3.5
Ash	1.3	4.7
Calcium	0.15	0.54
Phosphorus	0.14	0.49
Sodium	0.08	0.28
Potassium	0.30	1.1
Magnesium	0.01	0.04
Chloride	0.11	0.41
Omega-6 Polyunsaturated Fatty Acid	0.6	2.3
Omega-3 Polyunsaturated Fatty Acid	2.07	7.3
Arginine	0.89	3.2

5

To determine the effect of the food composition described in Table IV in reducing damage to normal skin and mucosa cells when fed to dogs with cancer undergoing radiation therapy, twelve dogs with histologically confirmed malignant neoplasia of the nasal cavity were selected sequentially from a patient population drawn from a Comparative Oncology Unit at a State

10 University. Dogs were excluded from this study if they were cachectic or if they had received chemotherapy, exogenous steroids, or anesthesia in the 30 days before selection for the study. In addition, dogs with concurrent diseases such as renal failure, hepatic cirrhosis, endocrine diseases, obesity, or hypercalcemia were excluded.

15 All dogs were entered into a study of double-blind randomized design and fed one of two diets designated "Diet 1" and "Diet 2". The diets were isocaloric providing 6.1 kJ metabolizable

energy/g. Each dog was exclusively fed isocaloric amounts (maintenance energy requirement (kcal = 2[70 weight kg 0.75]) of one of the two diets included in the study. Diet 1 had an ingredient composition of the present invention as described in Table IV. Diet 2, the control diet, was identical to Diet 1 except soybean oil was substituted for the menhaden fish oil and arginine

5 ingredients present in Diet 1, so Diet 2 contained lower levels of omega-3 fatty acids and arginine than Diet 1. Evaluation periods were baseline 1 week prior to the start of radiation therapy (designated "Day 0"), 7 days into radiation therapy, and 21 and 42 days after radiation therapy was completed.

10 The serum fatty acid concentrations of the omega-3 and omega-6 fatty acids in blood drawn from the patients over the evaluation period are recorded in Table V below.

TABLE V
Serum Fatty Acid Concentrations

	<u>Elapsed time in days</u>				
	0	7	21	42	
Omega 3 Fatty Acids		<u>Serum Concentration (μmol/L)</u>			
• Docosahexaenoic Acid (C22:6)					
Diet 1	1.95	21.13	18.70	22.81	
Diet 2	3.96	5.16	3.48	3.66	
• Eicosapentaenoic Acid (C20:5)					
Diet 1	1.03	17.95	18.0	25.93	
Diet 2	1.16	0.80	1.02	1.10	
Omega-6 Fatty Acids					
• Linoleic Acid (C18:2)					
Diet 1	73.92	34.45	31.26	25.96	
Diet 2	62.84	88.32	69.12	58.26	

15 The data recorded in Table V show that dogs fed Diet 1, the diet of the present invention, had significantly ($p < 0.001$) higher serum levels of the omega-3 polyunsaturated fatty acids, docosahexaenoic acid (C22:6) and eicosapentaenoic acid (C20:5); and reduced concentrations of the omega 6 polyunsaturated fatty acid, linoleic acid (C18:2) as compared to baseline (Day 0) and dogs fed Diet 2.

These increased serum omega-3 polyunsaturated fatty acids, docosahexanoic (C22:5) and eicosapentaenoic (C20:5) levels were determined to be significantly (p = statistical significance of difference from zero) associated with lower tissue concentrations of inflammatory mediators as reported in Tables VI and VII which follow. The level of inflammatory mediators provide

5 biochemical evidence of decreased damage to skin and mucosa.

Study parameters examined to evaluate the effect of Diet 1 and Diet 2 on ameliorating radiation damage were the generation of inflammatory mediators prostaglandin E₂, (PGE₂), 11-dehydrothromboxane B₂ (11 DTX B₂), as well as histologic scores evaluated from 6 mm punch 10 biopsies taken from the skin and oral mucosa from areas of high (300 cGy) and low (200 cGy) daily radiation dosages are recorded in Tables VI-VII below.

Table VI below records the presence in a sample taken from the inner lip (oral mucosa) of the patient of the inflammatory mediators PGE₂ and 11DTXB₂ which are biochemical markers for 15 inflammation.

TABLE VI
Rank correlation of serum fatty acids with oral mucosal inflammatory mediators.

Oral Mucosal Inflammatory Mediators			
Omega-3 Fatty Acids		PGE₂	11DTXB₂
• Docosahexanoic Acid (C22:6)	Coefficient of correlation	-0.11299	-0.15750
	p	0.2313	0.0942
• Eicosapentaenoic Acid (C20:5)	Coefficient of correlation	-0.22354	-0.21390
	p	0.0168	0.0223
Omega-6 Fatty Acids			
• Linoleic Acid (C18:2)	Coefficient of correlation	0.04855	0.31450
	p	0.6079	0.0007

The data recorded in Table VI show a negative correlation for the omega-3 polyunsaturated 20 fatty acids, docosahexanoic and eicosapentaenoic acids, that is, the higher the omega-3 fatty acid level present in the sample the lower the inflammation encountered by the patient. The data further show a positive correlation for the omega-6 fatty acid, linoleic acid, namely, the higher the omega-6 polyunsaturated fatty acid level, the higher the mediator level and the higher the level of inflammation encountered by the patient.

25 Table VII below records the presence, in a sample taken from the skin surface of the patient, of the inflammatory mediators PGE₂ and 11DTXB₂.

TABLE VII

Rank correlation of serum fatty acids with skin inflammatory mediators.

		<u>Skin Inflammatory Mediators</u>	
Omega-3 Fatty Acids		PGE2	11DTXB ₂
• Docosahexaenoic Acid (C22:6)	Coefficient of correlation p	-0.13259 0.01596	-0.16783 0.0769
• Eicosapentaenoic Acid (C20:5)	Coefficient of correlation p	-0.2729 0.0040	-0.16456 0.0829
Omega-6 Fatty Acids			
• Linoleic Acid (C18:2)	Coefficient of correlation p	0.15504 0.0995	0.23658 0.0120

The data recorded in Table VII shows that skin concentrations of inflammatory mediators were statistically significantly lower by rank correlation in patients with high levels of the omega-3 fatty acids, eicosapentaenoic and docosahexaenoic acids. Lower concentrations of inflammatory mediators are believed to play a role in ameliorating acute side effects of radiation therapy.

The data recorded in Table VIII below indicate that serum docosahexaenoic and eicosapentaenoic acid levels are also significantly associated with histologic evidence of decreased damage to the oral mucosa. Eicosapentaenoic and docosahexaenoic acid serum concentrations were determined to be positively correlated with cell thickness in mucosal areas, eicosapentaenoic acid (p=0.0171) and docosahexaenoic acid (p=0.0241).

TABLE VIII

Rank correlation of serum fatty acids with histology score of oral mucosal cells.

		<u>Histology Score for Oral Mucosa Cells</u>
Omega-3 Fatty Acids		
• Docosahexaenoic Acid (C22:6)	Coefficient of correlation p	0.25664 0.0171
• Eicosapentaenoic Acid (C20:5)	Coefficient of correlation p	0.24314 0.0241
Omega-6 Fatty Acids		
• Linoleic Acid (C18:2)	Coefficient of correlation p	-0.13776 0.2059

The data recorded in Table VIII shows that the patients with the overall highest eicosapentaenoic and docosahexaenoic acid serum concentrations had the best histological cell layer thickness scores in mucosal areas which is believed to provide for decreasing mucositis, thus improving quality of life in patients undergoing radiation therapy.

5

Quality of life in these cancer patients undergoing radiation therapy was further assessed using a clinical performance-scoring scheme where a lower score indicates better clinical performance. As shown in Table IX, serum eicosapentaenoic and docosahexaenoic acid had a significant negative rank correlation with clinical performance status, that is, the higher the omega-3 fatty acid level present in the sample the lower the score on clinical performance scoring scheme indicating better clinical performance.

10

TABLE IX

Rank correlation of serum fatty acids with clinical performance status.

		<u>Clinical Performance</u>
Omega-3 Fatty Acids		
• Docosahexaenoic Acid (C22:6)	Coefficient of correlation	-0.36840
p		0.0139
• Eicosapentaenoic Acid (C20:5)	Coefficient of correlation	-0.31893
p		0.0349
Omega-6 Fatty Acids		
• Linoleic Acid (C18:2)	Coefficient of correlation	0.22244
p		0.1467

The procedures for analysis from which the data recorded in Tables V -VIII were obtained 15 are described below.

Fatty Acid Analysis

Fatty Acids were analyzed following the procedure of Zicker et al as described in Ohta A, Mayo MC, Kramer N, Lands WE. Rapid analysis of fatty acids in plasma lipids. Lipids 1990; 20: 25:742-747.

Histopathology

The oral mucosa and skin were biopsied with a 6mm Baker's biopsy punch in areas receiving low (200 cGy) and high (300 cGy) radiation dosages as determined by computerized 25 treatment planning. Biopsies were performed 1 week prior to therapy, 1 day into therapy, 7 days

into therapy, at the end of therapy, and 21 days after therapy was completed. Tissues were evaluated histopathologically by a single pathologist for cell layer thickness.

Inflammatory mediator analysis

5 Oral mucosa and skin from areas receiving low and high radiation dosage were obtained the
same as for histopathology and frozen at -80°C. Frozen samples were placed on a clean glass slide
and cut into small pieces before thawing could occur. Cut pieces were transferred into a 4 ml
10 plastic culture tube and 2 ml of cold ethyl acetate was added. The sample was then homogenized
at highest speed setting for one minute while sample and culture tube were sitting in an ice bath.
Sample and culture tubes were then removed from the homogenizer and the homogenizer tip was
rinsed with one ml cold ethyl acetate. Rinse and sample were combined. Culture tubes were
15 capped with aluminum foil and set in an ice bath for 30 minutes. After thirty minutes in ice bath,
the tubes were capped and centrifuged at 500g for ten minutes at five degrees C. All supernatant
was removed and put into a new four ml plastic culture tube. Ethyl acetate was evaporated from
the sample with a slow stream of nitrogen gas. A warm (30°C) water bath was used to facilitate
drying. Sample residue was resuspended in 500ul EIA buffer (Caymen, Ann Arbor, MI). The
sample was capped with nitrogen gas and stored at -80°C. Samples were analyzed for
20 prostaglandin E₂ and, 11-dehydro-Thromboxane B₂ with Enzyme Immunoassay kits (Caymen,
Ann Arbor, MI).

CLAIMS

What is claimed is:

- 5 1. A method for mitigating the damaging effects to normal cells of a pet animal with cancer undergoing radiation therapy comprising a nutritionally balanced pet food, containing omega-6 polyunsaturated fatty acids, supplementing the food with a mixture of omega-3 polyunsaturated fatty acids and arginine and then feeding the food to the animal at least during the period of time during which the animal is exposed to radiation.
- 10 2. The method of claim 1 wherein the omega-3 polyunsaturated fatty acids are present in the food composition at a concentration of about 2.5 to about 7.5% on a dry matter basis.
- 15 3. The method of claim 1 wherein arginine is present in the food composition at a concentration of about 2.0 to about 3.5% on a dry matter basis.
4. The method of claim 1 wherein the weight ratio of omega-3 polyunsaturated fatty acids to omega-6 fatty acids present in the food is about 0.3:1 to 3.5:1.
- 20 5. The method of claim 1 wherein the nutritionally balanced food has a fat content of about 27 to 35% on a dry matter basis, a carbohydrate content of about 15 to about 27% on a dry matter basis and the weight ratio of omega-3 to omega-6 polyunsaturated fatty acids being in the range of about 0.3:1 to 3.5:1.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/14344A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/195 A61K31/20 A61K31/23 A23K1/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A23K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 567 433 A (SANDOZ NUTRITION LTD) 27 October 1993 (1993-10-27) page 6, line 10 - line 20 claims 1,3,11,14-18 ---	1-4
Y	WO 97 13415 A (COLGATE PALMOLIVE CO ;OGILVIE GREGORY K (US)) 17 April 1997 (1997-04-17) cited in the application example claims 1-9 ---	1-4
A	EP 0 367 724 A (SANDOZ AG ;SANDOZ AG (DE); SANDOZ AG (AT)) 9 May 1990 (1990-05-09) page 4, line 51 -page 5, line 6 claims 1,2,4,9-12 ---	1 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

G document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

26 October 1999

- 8. 11. 1999

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patenttaan 2
NL - 2230 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dekeirel, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/14344

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 678 247 A (IAMS COMPANY) 25 October 1995 (1995-10-25) page 2, line 16 - line 34 page 3, line 37 - line 57 page 6, line 18 - line 32 examples 1-4 claims 1-20 ----	1
A	E.C. CODNER ET AL.: "Nutritional management of skin disease" COMPENDIUM ON CONTINUING EDUCATION FOR THE PRACTICING VETERINARIAN, vol. 15, no. 3, 1993, pages 411-423, XP002119942 US page 411, paragraph 3 -page 414, column 1, paragraph 1 page 416, column 2, paragraph 2 ----	1
A	CH. IBEN: "Ernährung nach Operationen am Gastrointestinaltrakt" WIENER TIERÄRZTLICHE MONATSCHRIFT, vol. 84, no. 12, 1997, pages 369-373, XP002120237 at page 369, Summary page 370, column 2, paragraph 4 - paragraph 5 ----	1
A	WO 87 01589 A (BRIGHAM & WOMENS HOSPITAL) 26 March 1987 (1987-03-26) claims 1,2,5-8 ----	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/14344

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-4 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/14344

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0567433	A 27-10-1993	US 5780039 A	14-07-1998	
		AT 143570 T	15-10-1996	
		AU 3706493 A	28-10-1993	
		CA 2094540 A	24-10-1993	
		DE 69305105 D	07-11-1996	
		DE 69305105 T	13-03-1997	
		DK 567433 T	25-11-1996	
		ES 2092266 T	16-11-1996	
		GR 3021361 T	31-01-1997	
		JP 6009384 A	18-01-1994	
		MX 9302318 A	31-03-1994	
WO 9713415	A 17-04-1997	US 5776913 A	07-07-1998	
		AU 707341 B	08-07-1999	
		AU 7254596 A	30-04-1997	
		CA 2234249 A	17-04-1997	
		EP 0854681 A	29-07-1998	
		NO 981593 A	09-06-1998	
		NZ 319911 A	23-12-1998	
EP 0367724	A 09-05-1990	AT 85525 T	15-02-1993	
		AU 626930 B	13-08-1992	
		AU 4386089 A	03-05-1990	
		CA 2001727 A,C	30-04-1990	
		DK 540389 A	01-05-1990	
		ES 2052066 T	01-07-1994	
		HK 34694 A	22-04-1994	
		JP 2191213 A	27-07-1990	
		JP 2520488 B	31-07-1996	
		SG 30494 G	10-06-1994	
		US 5231085 A	27-07-1993	
EP 0678247	A 25-10-1995	AU 1652095 A	26-10-1995	
		CA 2147109 A	19-10-1995	
		JP 8038063 A	13-02-1996	
WO 8701589	A 26-03-1987	AT 152621 T	15-05-1997	
		AU 599335 B	19-07-1990	
		AU 6337886 A	07-04-1987	
		CA 1285491 A	02-07-1991	
		DE 3650620 D	12-06-1997	
		DE 3650620 T	11-09-1997	
		DK 241287 A	10-07-1987	
		EP 0238553 A	30-09-1987	
		JP 7094389 B	11-10-1995	
		JP 63501214 T	12-05-1988	
		US 5397803 A	14-03-1995	
		US RE35233 E	07-05-1996	
		US 5039704 A	13-08-1991	
		US 5763485 A	09-06-1998	
		US 5684045 A	04-11-1997	
		US 5607975 A	04-03-1997	
		US 4857555 A	15-08-1989	